title: Novel viral vectors utilizing intron splice-switching to activate genome rescue, expression and replication in targeted cells.
abstract: BACKGROUND
  The outcome of virus infection depends from the precise coordination of viral gene expression and genome replication. The ability to control and regulate these processes is therefore important for analysis of infection process. Viruses are also useful tools in bio- and gene technology; they can efficiently kill cancer cells and trigger immune responses to tumors. However, the methods for constructing tissue- or cell-type specific viruses typically suffer from low target-cell specificity and a high risk of reversion. Therefore novel and universal methods of regulation of viral infection are also important for therapeutic application of virus-based systems.
  
  
  METHODS
  Aberrantly spliced introns were introduced into crucial gene-expression units of adenovirus vector and alphavirus DNA/RNA layered vectors and their effects on the viral gene expression, replication and/or the release of infectious genomes were studied in cell culture. Transfection of the cells with splice-switching oligonucleotides was used to correct the introduced functional defect(s).
  
  
  RESULTS
  It was demonstrated that viral gene expression, replication and/or the release of infectious genomes can be blocked by the introduction of aberrantly spliced introns. The insertion of such an intron into an adenovirus vector reduced the expression of the targeted gene more than fifty-fold. A similar insertion into an alphavirus DNA/RNA layered vector had a less dramatic effect; here, only the release of the infectious transcript was suppressed but not the subsequent replication and spread of the virus. However the insertion of two aberrantly spliced introns resulted in an over one hundred-fold reduction in the infectivity of the DNA/RNA layered vector. Furthermore, in both systems the observed effects could be reverted by the delivery of splice-switching oligonucleotide(s), which corrected the splicing defects.
  
  
  CONCLUSIONS
  Splice-switch technology, originally developed for genetic disease therapy, can also be used to control gene expression of viral vectors. This approach represents a novel, universal and powerful method for controlling gene expression, replication, viral spread and, by extension, virus-induced cytotoxic effects and can be used both for basic studies of virus infection and in virus-based gene- and anti-cancer therapy.
authors: Institute of Technology, University of Tartu, Tartu, Estonia.
authors: Liane
authors: L
authors: Viru
authors: Gregory
authors: G
authors: Heller
authors: Taavi
authors: T
authors: Lehto
authors: Kalle
authors: K
authors: Pärn
authors: Samir
authors: S
authors: El Andaloussi
authors: Ülo
authors: Ü
authors: Langel
authors: Andres
authors: A
authors: Merits
references: Biochemistry. 1998 May 5;37(18):6235-9
references: 9572837
references: Handb Exp Pharmacol. 2009;(189):243-63
references: 19048203
references: Intern Med. 1992 Feb;31(2):269-72
references: 1600278
references: Viral Immunol. 2004;17(4):516-27
references: 15671748
references: Hum Gene Ther. 2004 May;15(5):509-18
references: 15144580
references: Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12400-5
references: 8901593
references: J Virol. 2010 Nov;84(22):11679-95
references: 20826696
references: Biotechnol Bioeng. 2003 Mar 5;81(5):553-62
references: 12514804
references: Virol J. 2009 Mar 24;6:33
references: 19317912
references: Curr Opin Mol Ther. 2008 Apr;10(2):140-9
references: 18386226
references: Curr Opin Mol Ther. 2010 Oct;12(5):530-7
references: 20886384
references: J Virol. 2002 May;76(9):4655-61
references: 11932433
references: Prog Nucleic Acid Res Mol Biol. 2002;71:187-222
references: 12102555
references: Future Oncol. 2010 Apr;6(4):619-34
references: 20373873
references: Gene Ther. 2009 Feb;16(2):291-6
references: 18818670
references: Mol Ther. 2011 Jan;19(1):9-15
references: 20978473
references: J Virol. 2006 Jun;80(12):5686-96
references: 16731907
references: J Gene Med. 2007 Jun;9(6):498-510
references: 17471591
references: J Virol. 1996 Jan;70(1):508-19
references: 8523564
references: J Virol Methods. 2008 Mar;148(1-2):265-70
references: 18054090
references: Virus Res. 2000 Jul;68(2):99-107
references: 10958981
references: Oligonucleotides. 2009 Mar;19(1):1-13
references: 19125639
references: Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8673-7
references: 8378346
references: Mol Ther. 2006 Oct;14(4):471-5
references: 16854630
references: J Gen Virol. 2007 Apr;88(Pt 4):1225-1230
references: 17374766
references: J Virol. 1991 Aug;65(8):4107-13
references: 2072446
references: Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1205-10
references: 19164558
references: Nat Biotechnol. 2005 Jun;23(6):718-23
references: 15883585
references: Cancer Res. 2000 Jan 15;60(2):334-41
references: 10667585
references: Biochem J. 2008 Jun 1;412(2):307-13
references: 18271753
references: Biotechnology (N Y). 1991 Dec;9(12):1356-61
references: 1370252
references: J Virol. 2004 Aug;78(16):8455-67
references: 15280454
references: J Virol. 2010 Mar;84(5):2352-64
references: 20015978
references: Cancer Biol Ther. 2009 Aug;8(15):1480-8
references: 19571664
references: J Virol. 2010 Aug;84(15):7543-57
references: 20484502
references: Mol Ther. 2008 Aug;16(8):1437-43
references: 18560417
references: Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):185-95
references: 20211577
references: Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2509-14
references: 9482916
references: Nucleic Acids Res. 2010 Dec;38(22):8348-56
references: 20719743
references: Expert Opin Biol Ther. 2010 Mar;10(3):353-68
references: 20132057
references: Clin Cancer Res. 2010 Jun 1;16(11):3067-77
references: 20484020
references: Cell. 1983 Jul;33(3):695-703
references: 6871991
references: Arch Virol. 1998;143(12):2443-51
references: 9930200
references: Expert Rev Mol Med. 2008 Nov 11;10:e33
references: 19000329
references: Nat Med. 1997 Jun;3(6):639-45
references: 9176490
references: Proc Natl Acad Sci U S A. 1979 Aug;76(8):3665-9
references: 291030
references: Gene Ther. 2009 Feb;16(2):252-61
references: 18946496
references: Mol Ther. 2008 Jul;16(7):1316-22
references: 18461057
references: Cell. 1981 Dec;27(2 Pt 1):289-98
references: 6895866